Skip to main content

View full-text article in PMC

. 2018 May 25;9(40):26019–26031. doi: 10.18632/oncotarget.25419

Table 4. Ibrutinib and idelalisib pharmacological profile in the proliferative fraction according to their clinical and biological parameters.

		Idelalisib			Ibrutinib
		AUC	N	P-value	AUC	N	P-value
Stage	A	1002	8	0.71	2257	8	0.50
Stage	B+C	830	5	0.71	1664	5	0.50
IGHV status	Mutated	1049	5	0.74	2519	5	0.40
IGHV status	Unmutated	894	8	0.74	1669	8	0.40
CD38 expression	≥20%	504	5	0.12	1179	5	0.18
CD38 expression	≤20%	1206	8	0.12	2560	8	0.18
Trisomy 12	Positive	213	2	0.18	522	2	0.26
Trisomy 12	Negative	1040	11	0.18	2141	11	0.26
del(13q)	Positive	1670	4	0.01	3507	4	0.02
del(13q)	Negative	577	9	0.01	1174	9	0.02
del(11q)	Positive	596	3	0.45	696	3	0.20
del(11q)	Negative	1008	10	0.45	2251	10	0.20
del(17p)	Positive	850	2	0.90	1727	2	0.86
del(17p)	Negative	926	12	0.90	1962	12	0.86